계명대학교 의학도서관 Repository

Basiliximab Does Not Reduce the Early Rejection Incidence in High-Risk Kidney Recipients Under Tacrolimus-Based Immunosuppression

Metadata Downloads
Author(s)
W.H. ChoH.J. LeeH.T. KimE.A. HwangS.Y. HanS.B. ParkH.C. Kim
Keimyung Author(s)
Cho, Won HyunKim, Hyoung TaeHwang, Eun AhHan, Seung YeupPark, Sung BaeKim, Hyun Chul
Department
Dept. of Surgery (외과학)
Dept. of Internal Medicine (내과학)
Institute for Medical Science (의과학연구소)
Journal Title
Transplantation Proceedings
Issued Date
2008
Volume
40
Issue
7
Abstract
This study sought to evaluate the benefit of addition of basiliximab to tacrolimus-based immunosuppression among high-risk renal transplantations. We retrospectively analyzed the clinical data of the basiliximab induction group (n = 55) and a risk-matched control group (n = 57). Graft survivals rates at 1, 3, and 5 years were 100%, 98.1%, and 91.8%, respectively, for the control and 96.2%, 93.9%, and 76.4%, respectively, for the basiliximab group (P = .083). Patient survivals rates at 1, 3, and 5 years were 98.3%, 98.3%, and 98.3%, respectively, for the control group and 98.2%, 94.2%, and 94.2%, respectively, for the basiliximab group (P = .277). Biopsy-proven acute rejection (AR) within 12 months occurred among 24.6% and 18.2% for the control and induction groups, respectively (P = .492). Serum creatinine levels at 1, 3, 6, and 12 months were 1.23 ± 0.30, 1.38 ± 0.41, 1.47 ± 0.61, and 1.44 ± 0.67 mg/dL, respectively, among the control and 1.24 ± 0.28, 1.40 ± 0.38, 1.40 ± 0.36, and 1.63 ± 1.62 mg/dL, respectively, among the induction group. In conclusion, this study showed that the addition of basiliximab to tacrolimus-based immunosuppression did not further improve the results of high-risk kidney transplantations in terms of reducing AR, prolonging graft survival, or improving renal function.



The development of powerful immunosuppressants has improved the early results of kidney allografts. Anti-CD25 antibody, basiliximab, showed further reduction of acute rejection (AR) among kidney transplantations under cyclosporine (CsA)-based immunosuppression. Tacrolimus (TAC), another powerful immunosuppressant, has been substituted for CsA.1 A combination of potent immunosuppressants usually reduces AR and enhances graft survival but can be associated with increased toxic side effect infection, or malignancy rates. We retrospectively analyzed our experience to see whether the addition of basiliximab to TAC-based immunosuppression further improved high-risk renal transplantations.
Keimyung Author(s)(Kor)
조원현
김형태
황은아
한승엽
박성배
김현철
Publisher
School of Medicine
Citation
W.H. Cho et al. (2008). Basiliximab Does Not Reduce the Early Rejection Incidence in High-Risk Kidney Recipients Under Tacrolimus-Based Immunosuppression. Transplantation Proceedings, 40(7), 2234–2236. doi: 10.1016/j.transproceed.2008.06.029
Type
Article
ISSN
0041-1345
Source
https://www.sciencedirect.com/science/article/pii/S0041134508007768?via%3Dihub
DOI
10.1016/j.transproceed.2008.06.029
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34727
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
3. Research Institutues (연구소) > Institute for Medical Science (의과학연구소)
Authorize & License
  • Authorize공개
  • EmbargoForever
Files in This Item:

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.